VERICEL CORPORATION Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
VERICEL CORPORATION (VCEL) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of -$2.17 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-02-26
- VERICEL CORPORATION effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2025 was -$2.17M.
- VERICEL CORPORATION effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was -$4.60M, a 286.66% decline from fiscal 2023.
- VERICEL CORPORATION effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2023 was $2.47M, a 26.23% decline from fiscal 2022.
- VERICEL CORPORATION effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2022 was $3.34M, a 49.09% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 6 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | -$2.17M 10-K · filed 2026-02-26 | ||
| 2024-12-31 | -$4.60M 10-K · filed 2026-02-26 | ||
| 2023-12-31 | $2.47M 10-K · filed 2026-02-26 | ||
| 2022-12-31 | $3.34M 10-K · filed 2025-02-27 | ||
| 2021-12-31 | $6.57M 10-K · filed 2024-02-29 | ||
| 2020-12-31 | $7.39M 10-K · filed 2023-02-23 | ||
| 2019-12-31 | $4.06M 10-K · filed 2022-02-24 | ||
| 2018-12-31 | $1.69M 10-K · filed 2021-02-24 | ||
| 2017-12-31 | -$5.45M 10-K · filed 2020-02-25 | ||
| 2016-12-31 | $7.68M 10-K · filed 2019-02-26 | ||
| 2015-12-31 | $10.67M 10-K · filed 2018-03-05 | ||
| 2014-12-31 | -$63.19M 10-K · filed 2017-03-13 | ||
| 2013-12-31 | $7.25M 10-K · filed 2016-03-14 | ||
| 2012-12-31 | $10.91M 10-K · filed 2015-03-25 | $8.13M 10-K · filed 2013-03-18 | |
| 2011-12-31 | $6.75M 10-K · filed 2014-03-13 | ||
| 2010-12-31 | $3.54M 10-K · filed 2013-03-18 | ||
| 2010-06-30 | $5.78M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |